Campaign brief: Two Shots. $40. Everywhere.

Doctors Without Borders/Médecins Sans Frontières (MSF) provides care and advocates for access to treatment and prevention for people living with and affected by HIV in low- and middle-income countries (LMICs). MSF provides pre-exposure prophylaxis (PrEP) to prevent HIV in people facing heightened risk. A gamechanger in PrEP is now here: lenacapavir (LEN), which only needs to be administered twice a year, and is nearly 100% effective. LEN has the potential to transform the global HIV response, especially for key populations at risk in LMICs. However, Gilead, the company that manufactures LEN, is keeping the drug out of reach for many. Gilead sells LEN at very high prices, severely restricts its supply from reaching certain countries, and refuses to sell LEN directly to MSF.

This brief presents MSF’s global campaign “Two Shots. $40. Everywhere”, calling on Gilead to reduce the price of LEN to less than $40 per person per year, increase its global supply to all LMICs, and sell the medicine directly to HIV prevention providers like MSF. The campaign also calls on governments to use all legal, policy, and other measures to break Gilead's monopoly and increase access to LEN for people everywhere.